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Summary. Background: Interaction of murine Gas6 with the
platelet Gas6 receptors Tyro3, Axl and Mer (TAM) plays an
important role in arterial thrombus formation. However, a role
for Gas6 in human platelet activation has been questioned.
Objective: To determine the role of Gas6 in human andmurine
platelet activation and thrombus formation. Methods and
Results: Gas6 levels appeared to be 20-fold higher in human
plasma than in platelets, suggesting a predominant role of
plasma-derived Gas6. Human Gas6 synergizes with ADP–
P2Y12 by enhancing and prolonging the phosphorylation of
Akt. Removal of Gas6 from plasma impaired ADP-induced
platelet aggregation. Under flow conditions, absence of human
Gas6 provoked gradual platelet disaggregation and inte-
grin aIIbb3 inactivation. Recombinant human Gas6 reversed
the effects ofGas6 removal. Inmouse blood, deficiency inGas6
or in one of the TAM receptors led to reduced thrombus
formation and increased disaggregation, which was completely
antagonized by external ADP. In contrast, collagen-induced
platelet responses were unchanged by the absence of Gas6 in
both human and mouse systems. Conclusions: The ADP–
P2Y12 and Gas6–TAM activation pathways synergize to
achieve persistent aIIbb3 activation and platelet aggregation.
We postulate a model of thrombus stabilization in which
plasma Gas6, by signaling via the TAM receptors, extends and
enhances the platelet-stabilizing effect of autocrine ADP,
particularly when secretion becomes limited.
Keywords: Akt, Gas6, platelet, TAM, thrombus stabilization.
Introduction
Gas6, encoded by growth arrest-specific gene 6, is a vitamin K-
dependent protein that is expressed in and released by many
cell types, including endothelial cells, vascular smooth muscle
cells, macrophages, and bone marrow cells [1–3]. Consistent
with its wide distribution, Gas6 has been implicated in a variety
of cellular functions, such as reversible growth arrest, survival,
proliferation, and inflammation [1,4,5]. The current under-
standing is that Gas6 exerts these functions by acting as an
extracellular ligand for receptor tyrosine kinases of the TAM
family, namely Tyro3, Axl, and Mer [6–8]. Activation of
phosphoinositide 3-kinase (PI3K) is an important downstream
effector of Gas6–Gas6 receptor signaling, as demonstrated by
studies in several cell types [5].
In mice, there is substantial evidence that the interaction of
Gas6 with TAM receptors on platelets has a stimulatory role in
thrombus formation in vivo. Interestingly, mice deficient in
Gas6 or any one of the TAM receptors were found to be
protected against venous and arterial thrombosis, without
having a bleeding phenotype [9,10]. AsGas6 also contributes to
plaque instability in Apoe)/) mice [3], it has become an
attractive target for the prevention or treatment of athero-
thrombosis. In mice, the binding of autocrine-secreted Gas6 to
the TAM receptors on activated platelets leads to inte-
grin aIIbb3 activation via PI3K [10]. However, ADP–P2Y12-
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mediated signaling also causes activation of aIIbb3 by a similar
route [11–13]. How the roles of Gas6 and ADP in platelet
activation and thrombus formation interact or overlap is still
unknown.
Whether Gas6 has a function in human platelet activation is
controversial. Whereas initial studies showed that Gas6
mRNA was detectable in human platelets [9,14], others have
found that human platelets neither store nor secrete Gas6
protein [15]. In human plasma, a variable level of Gas6 has
been measured, ranging from 15 to 65 lg/L [15–17]. However,
this variation in plasma Gas6 levels did not correlate with the
extent of initial platelet aggregation [18]. It has therefore been
questioned whether Gas6 contributes to the activation process
of human platelets. In the present study, we investigated the
contribution of plasma-derived Gas6 to human platelet
activation under static and flow conditions. We also compared
the roles of human and murine Gas6 in thrombus formation
and stabilization. The results lead to a model in which




Fibrillar Horm type I collagen was from Nycomed (Munich,
Germany). ADP and bovine serum albumin (BSA) were from
Sigma (St Louis, MO, USA). H-Phe-Pro-Arg chloromethyl
ketone (PPACK) was from Calbiochem (La Jolla, CA, USA).
Fluorescein isothiocyanate (FITC)-labeled annexin A5 was
from PharmaTarget (Maastricht, The Netherlands), and
FITC-labeled PAC-1 monoclonal antibody (mAb) was from
Becton-Dickinson (San Jose, CA, USA). Recombinant
human Gas6 (rhGas6) was from Abnova (Taipei, Taiwan).
Anti-human Gas6 antibody (Ab) (sc-1936), anti-human Gas6
Ab (sc-22759) and anti-human Axl Ab (sc-20741) were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Poly-
clonal anti-phosphoserine-473 Akt Ab and polyclonal anti-
Akt Ab were from Cell Signaling Technology (Danvers, MA,
USA).
Human blood and platelets
Human blood was drawn from healthy volunteers after full
informed consent had been obtained. Blood was collected into
17 vol.% acid–citrate–dextrose, 10 vol.% 129 mM trisodium
citrate, or 40 lM PPACK, as required. Platelet-rich plasma
(PRP), platelet-free plasma and washed platelets were obtained
as described [19]. For flow experiments, citrate-anticoagulated
plasma was recalcified with 7.5 mMCaCl2 and 3.75 mMMgCl2
in the presence of 40 lM PPACK [19].
Mouse blood and platelets
Experiments were approved by the local animal experimental
committees. Mice deficient in Gas6, Tyro3, Axl or Mer were
generated as previously described [9,20], and compared with
matched control wild-type mice of the same genetic back-
ground. All mice had platelet counts in the normal range.
Mouse blood was collected into 10 vol.% 129 mM trisodium
citrate and 1 U mL–1 heparin. Prior to flow experiments,
citrate-anticoagulated blood was recalcified, as described
above.
Immunoelectron microscopy
Resting and thrombin-stimulated platelets were fixed in a
mixture of 2% paraformaldehyde and 0.2% glutaraldehyde in
0.1 M phosphate buffer (pH 7.2). The samples were further
processed for cryoimmunoelectron microscopy, basically as
described previously [21]. In brief, fixed platelets were infiltrated
into 2.3 M sucrose and frozen in liquid nitrogen. Immunogold
labeling was performed with rabbit anti-human Gas6 or Axl
Abs on thin, frozen sections, using protein A/gold with 20-nm
gold particles. The sections were embedded in a mixture of
1.8% methylcellulose and 0.4% uranyl acetate. No labeling
reaction was visible in preparations incubated with a control
antibody.
Detection of Gas6 in human plasma and platelets
Human platelets (100 · 108 mL)1) were washed three times
in HEPES buffer (pH 6.6) (136 mM NaCl, 10 mM glucose,
5 mM HEPES, 2.7 mM KCl, 2 mM MgCl2, 2 mM CaCl2,
0.1% BSA), and then lysed in RIPA buffer containing a
cocktail of protease inhibitors [10]. The lysates were centri-
fuged at 15 000 ·g for 5 min to remove membrane frag-
ments. Supernatants were incubated overnight at 4 C with
an anti-Gas6 polyclonal Ab, coupled to protein A Sepharose
beads. Likewise, citrate-anticoagulated pooled platelet-free
plasma was incubated with beads containing anti-Gas6 Ab.
Beads were collected by centrifugation, washed twice in
phosphate-buffered saline, and eluted in sodium dodecylsul-
fate (SDS) sample buffer. Proteins were separated by SDS
polyacrylamide gel electrophoresis (SDS-PAGE) (7.5% poly-
acrylamide), transferred onto a poly(vinylidine fluoride)
membrane, and stained with goat anti-human Gas6 Ab.
Detection was with horseradish peroxidase-conjugated rabbit
anti-goat IgG, followed by enhanced chemiluminescence
(Pierce, Rockford, IL, USA).
Preparation of human Gas6-depleted plasma
Anti-human Gas6 Ab was coupled to aldehyde-activated bead
agarose resin by using the Seize primary immunoprecipitation
kit from Pierce. Pooled human citrate-anticoagulated plasma
was incubated overnight with aGas6 Ab-coupled resin at 4 C.
Supernatants of Gas6 Ab-treated and sham-treated plasmas
were frozen at ) 80 C until use. Full depletion of Gas6 was
verified by barium citrate precipitation of plasma samples,
followed by SDS-PAGE and western blotting, as described
previously [22].
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Platelet aggregation
Human platelet aggregation was measured by light-transmis-
sion aggregometry (Chronolog, Havertown, PA, USA) under
constant stirring at 1000 r.p.m. at 37 C [13]. Control and
Gas6-depleted plasmas (anticoagulated with citrate) were
reconstituted with washed human platelets at a final concen-
tration of 2.5 · 108 mL)1. Prior to addition of agonist, plasmas
were recalcified with 7.5 mM CaCl2 and 3.75 mM MgCl2 in the
presence of 40 lM PPACK. Alternatively, platelet aggregation
was determined by measuring single cell platelet counts with a
Coulter counter (Coulter Electronics, Hialeah, FL, USA).
Measurement of thrombus formation and phosphatidylserine
(PS) exposure
Degreased rectangular coverslips (24 · 60 mm) were coated
with fibrillar type I Horm collagen (25 lL of 200 lg colla-
gen mL)1), as described previously [13]. Coated coverslips were
inserted into a transparent parallel-plate perfusion chamber,
through which blood was perfused at a shear rate of 1000 s)1.
Secondary perfusion was with HEPES buffer (pH 7.45) or
recalcified citrate-anticoagulated plasma at the same shear rate.
Post-staining was with FITC-labeled annexin A5 (0.5 lg
mL)1) in CaCl2-containing HEPES buffer, as indicated.
Phase-contrast and fluorescence images were taken in real
time with a sensitive camera system [13]. Video recordings were
made simultaneously. Images were analyzed for surface area
coverage and for distribution of areas of individual segmented
features, as described previously [23]. For analysis of disaggre-
gation, the number of detaching (single or clustered) platelets
per individual aggregate were counted offline from video
recordings, as described previously [13].
Coverslips with thrombi were also examined with a Bio-
Rad 2100 multiphoton microscopic system (Zeiss, Jena, Ger-
many) [24]. Two-photon excitation was with a Spectra-Physics
Tsunami Ti:Sapphire laser (Mountain View, CA, USA), tuned
andmode-lockedat 800 nm,producingpulsesof 100 fs inwidth
(repetition rate of 82 MHz). The fluorescence from FITC-
labeledPAC-1(1 : 20)wasdetectedatanemissionwavelengthof
508–523 nm.Data forPAC-1binding toplatelets in a thrombus
werenormalized for theextentofplateletdeposition.Analysisof
confocal images was performed IMAGEPRO/LASERPIX software
(Media Cybernetics, Silver Spring,MD,USA).
Measurement of Akt activation
Akt activation was measured by western blot analysis of
platelet lysates [11]. A polyclonal anti-phosphoserine-473 Akt
Abwas used to detect active Akt, and a polyclonal anti-Akt Ab
to determine total Akt.
Statistics
Significance of differences was determined with the Mann–
Whitney U-test by using the statistical package for social
sciences (SPSS 11.0; SPSS, Chicago, IL, USA). Size distribution
of platelet aggregates was evaluated by chi-square analysis.
Results
Quantitative determination and localization of Gas6 and Axl
in human platelets
The literature is unclear on whether [9,14] or not [15] human
platelets express physiologically relevant amounts of Gas6. To
investigate this, we measured Gas6 levels in human platelets
and a corresponding volume of human plasma. Samples of
150 lL of plasma and 5 · 107 lysed platelets were subjected to
immunoprecipitation with beads coupled to anti-Gas6 Ab. A
normal platelet count of 3 · 108 mL)1 was assumed. Western
blots showed a single weak band at the size ofGas6 (75 kDa) in
the platelet immunoprecipitate. In contrast, precipitation of
plasma Gas6 gave a much denser band of the same size
(Fig. 1A). Staining of the blots with a mAb against c-
carboxyglutamate residues indicated that the Gas6 present in
both plasma and platelets was c-carboxylated (not shown). By
comparison with a reference sample of full-length rhGas6, the
Gas6 content in human plasma was estimated to be 20 lg L)1.
In contrast, the platelet Gas6 content was only 1 lg L)1
(equivalent to 5 ng per 109 platelets). These results thus
indicate that plasma is the major source of Gas6 in human
blood.
Immunoelectron microscopy was performed to determine
the intracellular location of Gas6 and its main receptor, Axl.
Quantitative analysis of sections from resting and thrombin-
stimulated platelets indicated that the fraction of Gas6 gold
label located near the plasma membrane increased from 14%
to 27%, with a corresponding decrease in the a-granules, the
remainder being predominantly in the open canicular system
(Fig. 1B,C). Similarly, stimulation of the platelets increased the
fraction of Axl gold label near the plasma membrane from
13% to 44%, again at the expense of granule-associated label
(Fig. 1D,E).
Plasma-derived Gas6 stabilizes aggregation of human
platelets
To study its role in platelet activation, Gas6 was depleted from
human pooled plasma. Depleted and control plasmas were
reconstituted with freshly isolated washed platelets from the
same donor. Just prior to addition of platelet agonists, the PRP
was recalcified with CaCl2/MgCl2 solution to obtainmillimolar
levels of both divalent cations. Millimolar levels of Ca2+ and
Mg2+ are required for physiologic regulation of integrin
activation [13]. PPACK was added to stop thrombin activity.
Treatment of the reconstituted Gas6-depleted PRP with
rhGas6 alone, up to 2 lg mL)1, did not evoke platelet
aggregation or shape change (Fig. 2A). Stimulation with a
suboptimal dose of ADP (10 lM) caused near-irreversible
aggregation in reconstituted control PRP, but transient aggre-
gation in reconstituted Gas6-depleted PRP. To confirm that
Human and murine Gas6 in thrombus stabilization 1799
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the difference was attributable to Gas6 depletion, rhGas6 was
pre-added to the PRP. Addition of rhGas6 (500 ng mL)1)
restored the impaired ADP-induced aggregation in Gas6-
depleted PRP, but did not influence the aggregation in control
PRP (Fig. 2B). Platelet aggregation induced by collagen
(5 lg mL)1) was only slightly impaired in Gas6-depleted
PRP in comparison with control PRP (Fig. 2C). A similar
level of impairment was observed at higher collagen concen-
trations (not shown). The rhGas6 was used here at a
concentration similar to that used in earlier studies [9]. Dose–
response curves of ADP-induced aggregation indicated half-
maximal stimulation at 70 ng rhGas6 mL)1 (range: 25–
500 ng mL)1) (Fig. 2D). This concentration is in the order of
the estimated plasma concentration of about 25 ng
Gas6 mL)1. Together, these data suggest that, in the human
system, plasma-derived Gas6 contributes to the stabilization of
platelet aggregate formation, particularly in response to ADP.
Synergy of Gas6 and ADP in Akt phosphorylation in human
platelets
In mouse platelets and other cell types, it has been demon-
strated that ligand occupation of the Gas6 receptors leads to
phosphorylation and activation of Akt by PI3K [5,10]. As the
PI3Kb/c isoforms and Akt play crucial roles in the ADP–
P2Y12-dependent sustained activation of integrin aIIbb3 [12,13],
we investigated how, in human platelets, Gas6 and ADP
receptor-mediated signaling contribute to Ser473 phosphory-
lation of Akt. Platelet stimulation with 10 lM ADP caused a
two-fold transient increase in Akt phosphorylation, with an
optimum between 10 and 20 min (Fig. 3A,B). In comparison,
stimulation with rhGas6 (500 ng mL)1) led to a gradual
increase in Akt phosphorylation, which crossed the level of
ADP-stimulated platelets after 30 min. The rhGas6-induced
Akt phosphorylation, however, completely relied on autocrine
P2Y12-mediated effects, as it was fully blocked by the P2Y12
antagonist AR-C69931MX (Fig. 3B). Strikingly, platelet acti-
vation with the combination of rhGas6 and ADP caused
greatly enhanced Akt phosphorylation in comparison with
ADP alone. This enhancement persisted for up to 45 min
(Fig. 3A,B). In sum, these results demonstrate synergy between
Gas6-evoked and ADP–P2Y12-evoked Akt phosphorylation.
Human plasma Gas6 contributes to stabilization of human
thrombi under flow by maintaining aIIbb3 activation
To investigate the functional implications of the synergy















Fig. 1. Quantitative determination and localization of Gas6 andAxl in human platelets. (A) Levels of Gas6 in human plasma and platelets were compared
by immunoprecipitating Gas6 from washed platelets (5 · 107) and from an equivalent amount of plasma (150 lL). A normal platelet count of
3 · 108 mL)1 was assumed. A representative western blot of the immunoprecipitates, after staining with anti-Gas6 antibody, is shown. Only plasma
immunoprecipitate gave a dense 75-kDa Gas6 band. (B–E) Immunoelectron microscopy localization of Gas6 and Axl in human platelets. Resting (B, D)
and thrombin-activated (C, E) platelets were fixed and incubated with anti-Gas6 antibody (B, C) or anti-Axl antibody (D, E), and this was followed by
immunogold labeling. Arrowheads denote gold label (scale bar: 1 lM). Note the presence of Axl staining near the plasma membrane in activated platelets.
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were carried out with whole blood under flow conditions. An
earlier established procedure was used, in which platelet
aggregates were preformed on immobilized collagen, after
which their tendency to disaggregate was measured upon
secondary perfusion with plasma [13]. Secondary perfusion for
10 min with control plasma resulted in the disappearance of
only a few platelets from the top of aggregates, the core
remaining stable (Fig. 4A). This contrasted with the results of
secondary perfusion experiments in the presence of the P2Y12
antagonist AR-C69931MX (ARC), where aggregates immedi-
ately started to disintegrate [13]. Secondary perfusion with
Gas6-depleted plasma also caused nearly complete thrombus
disintegration (Fig. 4A). However, interestingly, the majority
of platelets left the aggregates only after a period of 3 min
(Fig. 4B). Addition of rhGas6 (500 ng mL)1) toGas6-depleted
plasma reduced the number of disaggregation events almost to
the level seen in control plasma. After secondary perfusion, the
size distribution of remaining platelet features on the coverslip
was measured. Large platelet structures were present for both
control plasma and Gas6-depleted plasma with rhGas6, but
only smaller structures (< 40 platelets) were left after perfu-
sionwithGas6-depleted plasma (Fig. 4C). Further experiments
showed that addition of 20 lM ADP to Gas6-depleted plasma
completely prevented the disaggregation events. It was also
examined whether rhGas6 can contribute to thrombus stability
in the absence of P2Y12 activity. Therefore, secondary perfu-
sion was performed with plasma supplemented with ARC
(10 lM) with or without rhGas6 (1 lg mL)1). In the first
3 min, rhGas6 addition insignificantly changed the disaggre-
gation events from 5.3 ± 0.3 to 5.5 ± 0.25 per aggregate
[mean ± standard error of the mean (SEM), N = 3,
P = 0.67]. However, after 3 min of perfusion with rhGas6,
the disaggregation events tended to be reduced from 5.1 ± 0.4
to 4.4 ± 0.3 (P = 0.08). These results suggest that Gas6 can
compensate for a gradual decrease in ADP activity, but that it
cannot prevent platelet disaggregation upon full blockage of
the P2Y12 receptors.
The activation state of aIIbb3 in aggregates formed on
collagen-coated coverslips was investigated by post-staining
with fluorescence-labeled PAC-1 mAb and quantitative con-
focal image analysis. After 10 min of secondary perfusion with
control plasma, platelets on the surface showed high PAC-1
staining, indicating a high level of active aIIbb3 (Fig. 4D,E).
Whereas secondary perfusion with Gas6-deficient plasma led
to a significant reduction in PAC-1 staining, the addition of
rhGas6 to Gas6-depleted plasma completely restored this
staining. To verify that the reduced PAC-1 staining was not
a consequence of a reduction in platelet number, platelets
on the surface were post-stained with carboxyfluorescein
succinimidyl ester (CFSE). The ratio of PAC-1 to CFSE
fluorescent intensities was determined, and set at 1 for
secondary perfusion with control plasma. Secondary perfu-
sion with Gas6-depleted plasma reduced the PAC-1/CFSE
ratio to 0.28 ± 0.06, and this ratio increased to 0.75 ± 0.17
in the presence of rhGas6 (means ± SEM, n = 3, P =
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Fig. 2. Gas6 in humanplasma enhances platelet aggregation. (A–C)HumanGas6-depleted and control plasmas (citrate-anticoagulated) were reconstituted
with washed platelets from one donor (final concentration: 2.5 · 108 platelets mL–1 plasma). Prior to addition of agonist, plasmas were recalcified with
7.5 mM CaCl2 and 3.75 mM MgCl2 in the presence of 40 lM PPACK. Platelet aggregation was measured in response to (A) 500 ng mL
)1 recombinant
human Gas6 (rhGas6), (B) 10 lM ADP ± 500 ng mL)1 rhGas6, or (C) 5 lg mL)1 collagen. Aggregation traces are representative of four independent
experiments. (D)Dose–response curveof the effect of rhGas6onsingle cell platelet count (SPC) inGas6-depletedplatelet-richplasma (PRP)after stimulation
with 10 lM ADP for 2 min. The dotted line is the SPC of control (ctrl) PRP after stimulation with 10 lM ADP for 2 min. %T, percentage transmission.
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Gas6 from plasma leads to aIIbb3 inactivation and
subsequent disaggregation. In conclusion, these findings
point to an important role for human plasma-derived
Gas6 in late phases of aggregate stabilization, probably by
maintaining aIIbb3 in the active state.
Murine Gas6 and TAM receptors are required for stable
thrombus formation under flow
Mice lacking Gas6 or any of the three TAM receptors
display reduced arterial thrombus formation in various
experimental models [9,10,14]. In the present study, we used
blood from these mice to investigate the role of Gas6–Gas6
receptor interaction in the stabilization of thrombi formed
on collagen under moderately high shear flow conditions.
With blood from Gas6)/) mice, the platelet aggregates
formed on collagen were smaller in size and covered less of
the surface than wild-type aggregates (Fig. 5A,B). The
reduced aggregate formation was accompanied by a strong
increase in disaggregation events (platelets detaching from
the aggregates) (Fig. 5C). The ability of collagen-adhered
platelets to elicit glycoprotein (GP) VI-induced exposure of
PS was investigated by staining with FITC-labeled annexin
[24]. The numbers of PS-exposing platelets were similar with
Gas6)/) and Gas6+/+ blood (Fig. 5D), implying that Gas6
deficiency did not affect GPVI-induced procoagulant func-
tion. This was confirmed by experiments indicating that
collagen-induced thrombin generation was unaltered in PRP
from Gas6)/) mice in comparison with wild-type mice (not
shown).
Similar flow studies were performed with blood from mice
lacking one of the three TAM receptors (Fig. 5E–H). Again
smaller aggregates formed on collagen in comparison with
wild-type blood. Video analysis showed that platelets from
Tyro3)/), Axl)/) or Mer)/) mice detached more frequently
from the aggregates than corresponding wild-type platelets,
whereas the staining with FITC–annexin A5 remained un-
changed (Fig. 5G,H).
Given the synergy between Gas6 and ADP signaling, we
then investigated whether ADP could overcome the reduced
thrombus formation that was found in the absence of Gas6 or
Gas6 receptors.WhenADPwas coinfused withGas6)/) blood,
normal platelet aggregates formed on collagen with Gas6)/)
blood, and the number of disaggregation events was greatly
reduced (Fig. 6A–C). Similarly, coperfusion of ADP normal-
















































Fig. 3. Gas6 potentiates phosphorylation of Akt in ADP-stimulated human platelets. Washed human platelets (5 · 108 mL)1) were stimulated with ADP
(10 lM) and/or recombinant human Gas6 (rhGas6) (500 ng mL)1) for different time periods. Preincubation was with the P2Y12 receptor blocker
AR-C69931MX (10 lM) for 10 min, as indicated. (A) Platelet samples taken at indicated time points were analyzed for Ser473 phosphorylation of Akt
(P-Ser473) and for total Akt by western blotting. Representative blots are shown. (B) The graph represents quantification of the phosphorylation of Akt on
Ser473 (phosphorylated/total ratio). Data are means ± standard errors of the mean (n = 4–5).
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platelets (Fig. 6D,E). Thus, the Gas6–Gas6 receptor interac-
tion seems to become redundant for stable thrombus formation
once ADP is not a limiting factor.
Discussion
This study provides first evidence that Gas6 contributes to
platelet activation and thrombus stabilization in the human
circulatory system. The data show that, in human platelets,
Gas6 has a potent, enhancing effect on the P2Y12-dependent
activation of PI3K to phosphorylation of Akt. Interestingly,
Gas6 was unable to promote Akt phosphorylation if the P2Y12
receptors were blocked, but it potently enhanced and pro-
longed the phosphorylation resulting from ADP–P2Y12 recep-
tor stimulation. As the P2Y12-induced PI3K pathway is a
major route to aIIbb3 activation [12,25], this Gas6 effect leads to
more prolonged activation of the integrin.
In contrast to a report suggesting that Gas6 is absent in
human platelets [15], we were able to detect low levels of this
protein in human platelet preparations (5 ng per 109 platelets).
The difference is probably a result of the use of a more sensitive
detection method for protein on western blot by enhanced
chemiluminescence. For human blood, we report a 20-fold
higher concentration in pooled plasma ( 20 lg L)1) than in
platelets. The Gas6 concentration measured in plasma pools is
in agreement with the levels of 15–65 lg L)1 measured by
others [15–17]. For the murine system, almost six-fold higher
platelet Gas6 levels have been reported, whereas the plasma
Gas6 concentration is comparable [26]. The present data
suggest that plasma-derived Gas6 is responsible for the
majority of the effects of this protein in the human system.
However, this does not exclude the possibility that locally, for
example near a damaged vessel wall, levels of Gas6 can be





































































































































Fig. 4. Gas6 in human plasma preserves late thrombus stabilization and
aIIbb3 activation under flow. Human PPACK-anticoagulated whole blood
was perfused over a collagen-coated coverslip at a shear rate of 1000 s)1
for 4 min. Thrombi formed on the coverslip were secondarily perfused for
10 min with either control plasma or Gas6-depleted plasma at the same
flow rate. Supplementation with recombinant human Gas6 (rhGas6)
(500 ng mL)1) was as indicated. (A) Representative phase contrast images
(120 · 120 lm) of thrombi at the start and after 10 min of secondary
perfusion. (B) Number of disaggregation events per platelet aggregate
during initial (T = 0–3 min) and later (T = 3–10 min) periods of sec-
ondary perfusion. (C) Histogram of features left on the coverslip at the end
of secondary perfusion. Estimated numbers of platelets per feature are 1–2,
2–8, 8–40, 40–130, and > 130, as indicated. (D, E) Thrombi were stained
with fluorescein isothiocyanate (FITC)–PAC-1 monoclonal antibody
(1 : 20) to detect activated aIIbb3. Shown are representative fluorescent
images (180 · 180 lm) after secondary perfusion (D), and normalized
quantification of integrated FITC–PAC-1 fluorescence (FL) intensity (E).
Scale bar: 30 lm.Data aremeans ± standard errors of themean (n = 4).
*P < 0.05 as compared with control. (B, E), Mann–Whitney U-test. (C)
v2 analysis. AU, arbitrary units.
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Experiments to assess the role of plasma-derived Gas6 in
platelet aggregation and stabilization indicate that plasma-
derived Gas6 potentiates aggregation in stimulated human
platelets under static conditions. Under conditions of moderate
high shear, the use of Gas6-depleted plasma, unlike P2Y12
blockage, did not lead to immediate embolization of platelets,
but to delayed disaggregation, starting after several minutes.
Apparently, at earlier time points, other autocrine factors – in
particular, ADP – mask the involvement of Gas6. Given the































































































































































































































Fig. 5. Deficiency in murine Gas6 or one of the Gas6 receptors, Tyro3, Axl, or Mer (TAM), reduces thrombus formation and increases platelet
disaggregation under flow. Blood from wild-type (WT) mice or mice deficient in Gas6, Tyro3, Axl or Mer was passed over collagen-coated coverslips at a
shear rate of 1000 s)1 for 4 min. Phosphatidylserine (PS)-exposing platelets were stained by post-perfusion with fluorescein isothiocyanate (FITC)–
annexin A5. (A, E) Representative phase contrast (50 · 50 lm) and fluorescent (100 · 100 lm) images after perfusion. (B, F) Surface area coverage of
deposited platelets. (C, G) Quantification of detachment of platelets from thrombi (disaggregation) monitored during thrombus formation by real-time
video recording. Numbers indicate events per aggregate. (D, H) Surface area coverage of PS-exposing deposited platelets. Scale bar: 30 lm.
Means ± standard errors of the mean (n = 4); *P < 0.05.
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ADP by flow [13], and the rapid degradation of ADP by
plasma ectonucleotidases [27], it is conceivable that the
contribution of Gas6 signaling to aIIbb3 activation becomes
critical under these conditions. In human platelets, it is still
unclear which of the TAM receptors contributes to platelet
function. One study has shown that anti-TAM receptor Abs
impair agonist-induced platelet aggregation [28]. However, we
have been unable to reproduce this finding with preparations of
anti-human TAM receptor Abs, which were dialyzed to
remove azide (data not shown). Recently, it has been suggested
that themajority ofGas6 in plasma is bound to soluble Axl and
therefore incapable of stimulating platelet TAM receptors [29].
However, our functional studies do not support this suggestion,
as we found a consistent increase in Akt phosphorylation,
aIIbb3 activation and thrombus formation with native Gas6-
containing plasma or blood.
For mice, the data point to a remarkable similarity in the
phenotype of deficiency in Gas6 or in one of the TAM
receptors, in that thrombus formation on collagen under flow is
diminished, whereas the embolization of platelets from the
thrombi is increased. In both Gas6-deficient and TAM-
deficient mice, the defective thrombus formation could be fully
restored by coinfusion of ADP. This is compatible with a
mechanism whereby Gas6–TAM receptor and ADP–P2Y12
receptor signaling synergize to induce the same platelet
responses, leading to integrin activation and thrombus stabil-
ization. In contrast, the absence of Gas6 or TAM receptors
does not appear to impair platelet activation by collagen
receptors, as the GPVI-induced exposure of PS of platelets on
collagen was unchanged in all types of knockout blood.
Combined, these findings provide a mechanistic explanation
for earlier in vivo data showing reduced experimental throm-
bosis in mice lacking Gas6 or any of the TAM receptors [9,10],
and also for data showing that deficiencies in two or three of
the TAM receptors lead to a somewhat more severe platelet
dysfunction [30].
With the present findings, Gas6 is added to the growing list







































































































Fig. 6. Coperfusion with ADP normalizes thrombus formation in blood from mice deficient in Gas6 or Tyro3, Axl or Mer (TAM). Blood from mice
deficient in Gas6, Tyro3 or Axl or corresponding wild-type (WT) mice was coperfused with ADP (40 lM, final concentration) during flow over collagen at
1000 s)1 for 4 min. Phosphatidylserine-exposing platelets were stained by post-perfusion with fluorescein isothiocyanate–annexin A5. (A, D) Represen-
tative phase contrast (50 · 50 lm) and fluorescent (100 · 100 lm) images after perfusion. (B, E) Surface area coverage of deposited platelets. (C) Effect of
coinfusion with ADP on disaggregation during flow with Gas6+/+ and Gas6)/) blood. Scale bar: 30 lm. Data are means ± standard errors of the
mean (n = 4); *P < 0.05.
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themselves, but potentiate activation processes evoked by other
agonists. Interestingly, two such potentiating compounds,
insulin-like growth factor [31,32] and thrombopoietin [33], also
enhance Gi-induced or GPVI-induced signaling pathways via
PI3K and Akt phosphorylation. Also, the amplifying effects of
matrix metalloproteinase-2 and ephrinB1 are suggested to be
mediated, at least in part, by PI3K [34,35].
Together, the present results lead to an altered concept of the
roles of Gas6 and TAM receptors in thrombus formation
(Fig. 7). Receptors for ADP (P2Y12) and Gas6 (Tyro3, Axl,
and Mer) cooperate in the activation of PI3K to achieve
persistent activation of aIIbb3 and thrombus stabilization.
Initially, secreted ADP is sufficient to prevent embolization by
continuous P2Y12-mediated signaling [13]. However, the role of
autocrine ADP via P2Y12 receptor stimulation is time-
restricted, owing to the limited amount of ADP in platelets
and its rapid degradation by ectonucleotidases. At this point,
Gas6-induced signaling of TAM receptors via PI3K becomes
critical for persistent aIIbb3 activation and thrombus integrity.
Thus, whereas others have shown that, under shear, platelets
can also aggregate in the absence of integrin activation [36], our
data point also to a time-dependent and place-dependent role
of platelet-derived and plasma-derived platelet activators or
amplifiers in regulating the highly dynamic process of throm-
ADP secretion and increased
TAM receptor exposure
Synergistic action of




















Fig. 7. Synergistic roles of ADP and Gas6 in thrombus formation and stabilization. (A) Activation of platelets results in the secretion of autocrine agents
such as ADP and in increased exposure of Tyro3, Axl and Mer (TAM) receptors. (B) ADP (acting via P2Y12) and Gas6 (acting via TAM) jointly elicit
strong signaling via phosphoinositide 3-kinase (PI3K)–Akt to keep aIIbb3 in the activated state. (C) The availability of autocrine ADP is time-restricted,
owing to the limited amount of it in platelets and its rapid degradation by ectonucleotidases. At that point, Gas6-induced signaling of exposed TAM
receptors via PI3K becomes critical for persistent aIIbb3 activation and thrombus integrity.
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bus formation. Targeting one of these amplifiers, such as Gas6,
might provide a safe strategy for the development of new
antithrombotic agents.
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